An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:11/18/2012
Start Date:April 2011
Contact:Marco Palmas, MD
Email:netcare.infodesk@helsinn.com
Phone:0041-91-985 19 42

Use our guide to learn which trials are right for you!

A Phase III Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of the Efficacy and Safety of Oral Netupitant Administered in Combination With Palonosetron and Dexamethasone Compared to Oral Palonosetron and Dexamethasone for the Prevention of Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy


NETU-08-18 is a clinical study assessing efficacy and safety of a single oral dose of
netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with
oral dexamethasone. The objective of the study is to demonstrate that netupitant and
palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting
induced by moderately emetogenic cancer chemotherapy after administration of repeated
cycles of chemotherapy.


Inclusion Criteria:

- Naïve to cytotoxic chemotherapy. Previous biological or hormonal therapy will be
permitted.

- Scheduled to receive first course of an anthracycline and cyclophosphamide containing
moderately emetogenic chemotherapy (MEC) regimen for the treatment of a solid
malignant tumor: cyclophosphamide I.V. (500 to 1500 mg/m2) and I.V. doxorubicin (more
or equal to 40 mg/m2) or cyclophosphamide I.V. (500 to 1500 mg/m2) and I.V.
epirubicin (more or equal to 60 mg/m2).

- If scheduled to receive chemotherapy agents of minimal to low emetogenic potential
they could be given on any day.

- ECOG Performance Status of 0, 1, or 2.

- Female patients of either non-childbearing potential or child-bearing potential with
a commitment to use contraceptive methods throughout the clinical trial

- Hematologic and metabolic status adequate for receiving a moderately emetogenic
regimen based on laboratory criteria (Total Neutrophils,Platelets, Bilirubin, Liver
enzymes, Serum Creatinine or Creatinine Clearance)

The following inclusion criteria must be checked prior inclusion at each cycle of the
Multiple-Cycle Extension:

- Participation in the study during the next cycle of chemotherapy is considered
appropriate by the investigator Satisfactory study compliance in the preceding cycle
of chemotherapy and related study procedures.

- Scheduled to receive the same chemotherapy regimen as cycle 1

- Adequate hematologic and metabolic status as defined for cycle 1

Exclusion Criteria:

- If female, pregnant or lactating.

- Current use of illicit drugs or current evidence of alcohol abuse.

- Scheduled to receive any highly emetogenic chemotherapy (HEC) from Day 1 to Day 5 or
moderately emetogenic chemotherapy (MEC) from Day 2 to Day 5 following the allowed
MEC regimen.

- Received or is scheduled to receive radiation therapy to the abdomen or the pelvis
within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1.

- Any vomiting, retching, or mild nausea within 24 hours prior to Day 1.

- Symptomatic primary or metastatic CNS malignancy.

- Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial
pressure, hypercalcemia, an active infection or any uncontrolled medical condition
(other than malignancy) that, in the opinion of the investigator, may confound the
results of the study, represent another potential etiology for emesis and nausea
(other than chemotherapy-induced nausea and vomiting, CINV) or pose unwarranted risks
in administering the study drugs to the patient.

- Known hypersensitivity or contraindication to 5-HT3 receptor antagonists or
dexamethasone.

- Previously received an NK1 receptor antagonist

- Participation in a clinical trial involving oral netupitant administered in
combination with palonosetron.

- Any investigational drugs taken within 4 weeks prior to Day 1 of cycle 1, and/or is
scheduled to receive any investigational drug during the study.

- Systemic corticosteroid therapy at any dose within 72 hours prior to Day 1 of cycle
1.

- Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy.

- Any medication with known or potential antiemetic activity within 24 hours prior to
Day 1 of cycle 1

- Scheduled to receive any strong or moderate inhibitor of CYP3A4 or its intake within
1 week prior to Day 1.

- Scheduled to receive any of the following CYP3A4 substrates: terfenadine, cisapride,
astemizole, pimozide.

- Scheduled to receive any CYP3A4 inducer or its intake within 4 weeks prior to Day 1.

- History or predisposition to cardiac conduction abnormalities, except for incomplete
right bundle branch block.

- History of risk factors for Torsade de Point (heart failure, hypokalemia, family
history of Long QT Syndrome).

- Severe cardiovascular diseases, including myocardial infarction within 3 months prior
to Day 1, unstable angina pectoris, significant valvular or pericardial disease,
history of ventricular tachycardia, symptomatic Congestive Heart Failure (CHF) NYHA
class III-IV, and severe uncontrolled arterial hypertension.

- Any illness or condition that, in the opinion of the investigator, may confound the
results of the study or pose unwarranted risks in administering the investigational
product to the patient.

- Concurrent medical condition that would preclude administration of dexamethasone such
as systemic fungal infection or uncontrolled diabetes.

The following exclusion criteria must be checked prior inclusion at each cycle of the
Multiple-Cycle Extension:

- If female, pregnant or lactating

- Active infection or uncontrolled disease except for malignancy.

- Started any of the restricted medications.

- Any vomiting, retching, or mild nausea within 24 hours prior to Day 1.
We found this trial at
28
sites
Tacoma, Washington 98405
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
2320 S Seacrest Blvd # 300
Boynton Beach, Florida 33435
?
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
?
mi
from
Anniston, AL
Click here to add this to my saved trials
Bristol, Tennessee 37620
?
mi
from
Bristol, TN
Click here to add this to my saved trials
?
mi
from
Canton, OH
Click here to add this to my saved trials
Charleston, South Carolina 29403
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charleston, South Carolina
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Corona, CA
Click here to add this to my saved trials
?
mi
from
Corona, CA
Click here to add this to my saved trials
Corpus Christi, Texas 78412
?
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Denver, Colorado 80204
?
mi
from
Denver, CO
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Evansville, Indiana
?
mi
from
Evansville, IN
Click here to add this to my saved trials
Fountain Valley, California 92708
?
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Hagerstown, Maryland 21742
?
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Hazard, Kentucky
?
mi
from
Hazard, KY
Click here to add this to my saved trials
Hot Spring, Arkansas 71913
?
mi
from
Hot Spring, AR
Click here to add this to my saved trials
Jacksonville, Florida
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
Middletown, OH
Click here to add this to my saved trials
Mission Hills, California 91345
?
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Muscle Shoals, Alabama 35661
?
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
New Albany, Indiana 47150
?
mi
from
New Albany, IN
Click here to add this to my saved trials
Ogden, Utah 84403
?
mi
from
Ogden, UT
Click here to add this to my saved trials
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Whittier, California 90603
?
mi
from
Whittier, CA
Click here to add this to my saved trials
?
mi
from
Whittier, CA
Click here to add this to my saved trials
Winston-Salem, North Carolina
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Worcester, Massachusetts 01608
?
mi
from
Worcester, MA
Click here to add this to my saved trials